PF-Atlas › Clinical Trials › NCT03047031

Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

Nintedanib · Not specified

Registry ID
NCT03047031
Phase
Not specified
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Boehringer Ingelheim
Start
2017-04-05
Enrollment
21
Locations
8

About this trial

This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis. The safety of nintedanib has been assessed in clinical trials.This active surveillance aims to collect the safety data of 200 IPF patients treated with nintedanib in approved indication after the commercial availability of the drug in India (23rd January 2017). The objective is to look at safety of nintedanib in the real world setting.

View NCT03047031 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT03047031 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.